AIM:OBD · Health Care · Biotechnology / molecular diagnostics – precision medicine tests based on 3D genomics technology

Oxford Biodynamics plc

Oxford BioDynamics Plc (OBD) is an AIM-listed international biotechnology company commercialising its proprietary EpiSwitch 3D genomics platform for personalised healthcare. It has launched two commercial blood tests – EpiSwitch PSE (prostate cancer screening) and EpiSwitch CiRT (checkpoint inhibitor immunotherapy response) – and also undertakes biomarker discovery and clinical development work for pharma/biotech partners. The Group operates CLIA-accredited and ISO-accredited clinical laboratories in Oxford, UK and Frederick, MD, USA, plus a reference lab in Penang, Malaysia, and is developing a cloud platform, EpiSwitch Orion, on Google Cloud.

Export the Oxford Biodynamics plc factsheetfree account Open the FY2025 report

AIM:OBDClose, 23 Oct 2026

+4.5% on the day−63.5% over a year

Market cap£2.3m
52-week range0.1p – 0.3p
Free cash flow yield−347.2%
Shares traded a day34.7m

Prices to 23 Oct 2026 · ratios on the FY2025 accounts · not investment advice

The company

Admitted6 Dec 2016
Registered office3140 Rowan Place, John Smith Drive, Oxford Business Park South, Oxford, OX4 2WB, UK
IncorporatedUnited Kingdom
Employees41
Reports inGBP
Companies House06227084
Websiteoxfordbiodynamics.com
Chief executiveDr Jon Burrows
Finance directorPaul Stockdale
ChairIain G Ross
AuditorGrant Thornton UK LLPclean opinion in all 10 reports read · going-concern uncertainty in 6 · 1 change of auditor
Adviser and brokerShore Capital, Cassini House, 57 St James's Street, London SW1A 1LD
Next annual reportExpected 30 Jan 2027for the year to 30 Sept 2026

Share price and financials

0.1p at close on 23 Oct 2026 · 11 reported years, FY2015–FY2025

Years in viewFY2015 – FY2026

23 Oct 20260.1p−99.9% since 6 Dec 2016 166.0m traded

0.1p

Line	FY2015locked	FY2016locked	FY2017locked	FY2018locked	FY2019locked	FY2020locked	FY2021locked	FY2022locked	FY202509/25
Revenue	0.81	0.49	0.96	1.0	0.80	0.84	0.89	0.44
Gross profit	0.22	0.20	0.25	0.45	0.27	0.24	0.50	0.48
Operating profit	(14.3)	(10.4)	(15.7)	(9.5)	(9.9)	(15.7)	(9.0)	(7.8)
Net finance cost	0.33	0.19	0.20	0.36	0.33	0.42	0.22	0.39
Profit before tax	(13.3)	(7.2)	(10.1)	(14.1)	(15.4)	(13.2)	(8.8)	(13.7)
Tax charge	(0.28)	(0.58)	(0.56)	(0.51)	(0.53)	(0.37)	(0.27)	(0.59)
Profit for the year	(6.8)	(16.0)	(11.5)	(12.0)	(7.7)	(6.3)	(7.8)	(16.0)
EBITDA	(9.5)	(14.0)	(10.0)	(5.9)	(13.6)	(11.2)	(6.0)	(6.8)
Basic EPS	(2.59p)	(3.67p)	(4.59p)	(3.79p)	(4.71p)	(5.75p)	(4.99p)	(3.03p)
Diluted EPS	(2.62p)	(3.51p)	(5.60p)	(3.81p)	(4.57p)	(3.10p)	(2.92p)	(3.61p)
Dividend per share	0.00p	0.00p	0.00p	0.00p	0.00p	0.00p	0.00p	0.00p	—

GBP millions, negatives in brackets. Per-share lines in pence. later is what a following report restated the figure to; vs is a second reading that disagrees. The figure shown is the one the original filing printed, and both readings are kept. Click any figure: opens the report page it was read from, highlighted; shows how it was calculated. The share price above is drawn to the same columns: each close sits over the financial year it fell in.

2 figures

3 years, at a glance

GBP · %

Dashed: Operating margin, in % on its own scale — read its shape, not its height against the bars.

FY2025Revenue£1.1mOperating margin−1,011.3%